Nurix Therapeutics, Inc.
NRIX · Pharmaceutical Preparations · 103.4M shares · +8%/yr ↑ shares · EDGAR filings ↗
Reference price $20.06 · est. market cap ~$2.1B — last insider sale, 2026-06-25 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — targeted-protein-degradation clinical, heavy burn ($263M), funded.
Strengths
- Liquidity — current ratio 7.0 (70th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-263.5M)
- Net lossNet loss (net margin -314.9%)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $593M cash & investments, ~9 quarters of runway
- Insider sellingInsider selling — 20 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, ~$2M, last 6mo) Form 4 ↗
- Revenue declineRevenue -54.0% YoY
- Notable holderHeld by 6 notable fund(s): FMR LLC, STATE STREET CORP, ARK Investment Management LLC +3 more (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: RENAISSANCE TECHNOLOGIES LLC
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-340.2%
Net margin
-314.9%
Return on equity
-49.1%
Return on assets
-38.4%
Revenue growth (QoQ)
-54.0%
Current ratio
7.0×
Free cash flow
-$263M
EBITDA
-$277M
Tangible book value
$539M
Cash & investments
$593M
Cash runway
9q
Stock comp / revenue
45.2%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-25 | Ring Christine | Option exercise | 13K | $7.26 |
| 2026-06-25 | Ring Christine | Option exercise | 16K | $8.72 |
| 2026-06-25 | Ring Christine | Sell | 29K | $20.06 |
| 2026-06-25 | Hansen Gwenn | Sell | 5.4K | $20.00 |
| 2026-06-02 | Ring Christine | Option exercise | 3.4K | $1.86 |
| 2026-06-02 | Ring Christine | Sell | 8.1K | $16.60 |
| 2026-05-05 | van Houte Hans | Sell | 13K | $16.58 |
| 2026-05-05 | van Houte Hans | Sell | 582 | $17.18 |
| 2026-05-04 | Ring Christine | Sell | 8.1K | $16.96 |
| 2026-05-01 | Ring Christine | Sell | 5.4K | $16.76 |
| 2026-04-30 | van Houte Hans | Option exercise | 2.0K | — |
| 2026-04-30 | van Houte Hans | Option exercise | 3.8K | — |
| 2026-04-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2026-04-30 | van Houte Hans | Sell | 2.4K | $16.65 |
| 2026-04-30 | Ring Christine | Option exercise | 2.0K | — |
| 2026-04-30 | Ring Christine | Option exercise | 3.8K | — |
| 2026-04-30 | Ring Christine | Option exercise | 2.9K | — |
| 2026-04-30 | Ring Christine | Sell | 3.2K | $16.65 |
| 2026-04-30 | Hansen Gwenn | Option exercise | 2.0K | — |
| 2026-04-30 | Hansen Gwenn | Option exercise | 3.8K | — |
| 2026-04-30 | Hansen Gwenn | Option exercise | 2.9K | — |
| 2026-04-30 | Hansen Gwenn | Sell | 3.2K | $16.65 |
| 2026-04-02 | Ring Christine | Sell | 8.1K | $15.24 |
| 2026-03-02 | Ring Christine | Sell | 8.1K | $15.44 |
| 2026-02-09 | Ring Christine | Sell | 14K | $16.66 |
| 2026-02-03 | Hansen Gwenn | Option exercise | 31K | $0.84 |
| 2026-01-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2026-01-30 | van Houte Hans | Option exercise | 2.0K | — |
| 2026-01-30 | van Houte Hans | Option exercise | 3.8K | — |
| 2026-01-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2026-01-30 | van Houte Hans | Sell | 3.6K | $16.58 |
| 2026-01-30 | van Houte Hans | Sell | 73 | $17.37 |
| 2026-01-30 | Ring Christine | Option exercise | 1.9K | — |
| 2026-01-30 | Ring Christine | Option exercise | 2.0K | — |
| 2026-01-30 | Ring Christine | Option exercise | 3.8K | — |
| 2026-01-30 | Ring Christine | Option exercise | 2.9K | — |
| 2026-01-30 | Ring Christine | Sell | 4.3K | $16.58 |
| 2026-01-30 | Ring Christine | Sell | 88 | $17.37 |
| 2026-01-30 | Hansen Gwenn | Option exercise | 3.2K | — |
| 2026-01-30 | Hansen Gwenn | Option exercise | 2.0K | — |
| 2026-01-30 | Hansen Gwenn | Option exercise | 3.8K | — |
| 2026-01-30 | Hansen Gwenn | Option exercise | 2.9K | — |
| 2026-01-30 | Hansen Gwenn | Sell | 4.8K | $16.58 |
| 2026-01-30 | Hansen Gwenn | Sell | 98 | $17.37 |
| 2026-01-20 | Ring Christine | Option exercise | 3.8K | $1.86 |
| 2026-01-20 | Ring Christine | Sell | 3.8K | $18.42 |
| 2025-12-18 | Ring Christine | Option exercise | 3.8K | $1.86 |
| 2025-12-18 | Ring Christine | Sell | 3.6K | $17.87 |
| 2025-12-18 | Ring Christine | Sell | 200 | $18.55 |
| 2025-11-24 | Ring Christine | Option exercise | 38K | $1.86 |
| 2025-11-24 | Ring Christine | Sell | 38K | $17.07 |
| 2025-11-03 | van Houte Hans | Sell | 6.3K | $12.56 |
| 2025-10-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2025-10-30 | van Houte Hans | Option exercise | 2.0K | — |
| 2025-10-30 | van Houte Hans | Option exercise | 3.8K | — |
| 2025-10-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2025-10-30 | van Houte Hans | Sell | 3.1K | $12.80 |
| 2025-10-30 | Ring Christine | Option exercise | 1.9K | — |
| 2025-10-30 | Ring Christine | Option exercise | 2.0K | — |
| 2025-10-30 | Ring Christine | Option exercise | 3.8K | — |
| 2025-10-30 | Ring Christine | Option exercise | 2.9K | — |
| 2025-10-30 | Ring Christine | Sell | 3.6K | $12.80 |
| 2025-10-30 | Hansen Gwenn | Option exercise | 3.2K | — |
| 2025-10-30 | Hansen Gwenn | Option exercise | 2.0K | — |
| 2025-10-30 | Hansen Gwenn | Option exercise | 3.8K | — |
| 2025-10-30 | Hansen Gwenn | Option exercise | 2.9K | — |
| 2025-10-30 | Hansen Gwenn | Sell | 4.1K | $12.80 |
| 2025-09-17 | GREGORY JULIA P | Option exercise | 11K | $1.86 |
| 2025-08-01 | van Houte Hans | Sell | 5.4K | $11.03 |
| 2025-07-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2025-07-30 | van Houte Hans | Option exercise | 2.0K | — |
| 2025-07-30 | van Houte Hans | Option exercise | 3.8K | — |
| 2025-07-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2025-07-30 | van Houte Hans | Sell | 4.3K | $12.01 |
| 2025-07-30 | Ring Christine | Option exercise | 1.9K | — |
| 2025-07-30 | Ring Christine | Option exercise | 2.0K | — |
| 2025-07-30 | Ring Christine | Option exercise | 3.8K | — |
| 2025-07-30 | Ring Christine | Option exercise | 2.9K | — |
| 2025-07-30 | Ring Christine | Sell | 3.8K | $12.01 |
| 2025-07-30 | Hansen Gwenn | Option exercise | 3.2K | — |
| 2025-07-30 | Hansen Gwenn | Option exercise | 2.0K | — |
| 2025-07-30 | Hansen Gwenn | Option exercise | 3.8K | — |
| 2025-07-30 | Hansen Gwenn | Option exercise | 2.9K | — |
| 2025-07-30 | Hansen Gwenn | Sell | 4.3K | $12.01 |
| 2025-05-02 | van Houte Hans | Sell | 6.2K | $11.33 |
| 2025-04-30 | Hansen Gwenn | Option exercise | 3.2K | — |
| 2025-04-30 | Hansen Gwenn | Option exercise | 2.0K | — |
| 2025-04-30 | Hansen Gwenn | Option exercise | 3.8K | — |
| 2025-04-30 | Hansen Gwenn | Sell | 3.4K | $11.50 |
| 2025-04-30 | Ring Christine | Option exercise | 1.9K | — |
| 2025-04-30 | Ring Christine | Option exercise | 2.0K | — |
| 2025-04-30 | Ring Christine | Option exercise | 3.8K | — |
| 2025-04-30 | Ring Christine | Sell | 2.9K | $11.50 |
| 2025-04-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2025-04-30 | van Houte Hans | Option exercise | 2.0K | — |
| 2025-04-30 | van Houte Hans | Option exercise | 3.8K | — |
| 2025-04-30 | van Houte Hans | Sell | 2.4K | $11.50 |
| 2025-03-03 | van Houte Hans | Sell | 5.1K | $14.40 |
| 2025-03-03 | van Houte Hans | Sell | 700 | $15.13 |
| 2025-01-31 | Ring Christine | Option exercise | 223 | $1.86 |
| 2025-01-31 | Ring Christine | Option exercise | 5.5K | $1.86 |
| 2025-01-31 | Ring Christine | Sell | 5.7K | $19.94 |
| 2025-01-31 | Ring Christine | Sell | 100 | $20.48 |
| 2025-01-30 | Ring Christine | Option exercise | 1.9K | — |
| 2025-01-30 | Ring Christine | Option exercise | 2.0K | — |
| 2025-01-30 | Ring Christine | Option exercise | 3.8K | — |
| 2025-01-30 | Ring Christine | Sell | 2.9K | $19.81 |
| 2025-01-30 | Ring Christine | Sell | 291 | $20.33 |
| 2025-01-30 | Hansen Gwenn | Option exercise | 3.2K | — |
| 2025-01-30 | Hansen Gwenn | Option exercise | 2.0K | — |
| 2025-01-30 | Hansen Gwenn | Option exercise | 3.8K | — |
| 2025-01-30 | Hansen Gwenn | Sell | 3.4K | $19.81 |
| 2025-01-30 | Hansen Gwenn | Sell | 333 | $20.33 |
| 2025-01-30 | van Houte Hans | Option exercise | 2.9K | — |
| 2025-01-30 | van Houte Hans | Option exercise | 2.0K | — |
| 2025-01-30 | van Houte Hans | Option exercise | 3.8K | — |
| 2025-01-30 | van Houte Hans | Sell | 2.6K | $19.81 |
| 2025-01-30 | van Houte Hans | Sell | 254 | $20.33 |
| 2025-01-02 | Ring Christine | Option exercise | 5.8K | $1.86 |
| 2025-01-02 | Ring Christine | Sell | 5.8K | $19.50 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07221500 ↗ | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | PHASE2 | Recruiting | 2028-01-01 |
| NCT05131022 ↗ | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | PHASE1 | Recruiting | 2027-01-01 |
| NCT05107674 ↗ | A Study of NX-1607 in Adults With Advanced Malignancies Ovarian Cancer, Epithelial, Gastric Cancer | PHASE1 | Recruiting | 2026-08-31 |
| NCT04830137 ↗ | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | PHASE1 | Recruiting | 2026-05-01 |
| NCT06717269 ↗ | Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets Healthy Volunteer | PHASE1 | Recruiting | 2026-04-01 |
| NCT07520006 ↗ | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies B-cell Lymphoma, Chronic Lymphocytic Leukemia | PHASE1/PHASE2 | Not Yet Recruiting | 2033-05-01 |
| NCT07516093 ↗ | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL B-cell Lymphoma, Chronic Lymphocytic Leukemia | PHASE3 | Not Yet Recruiting | 2029-10-01 |
| NCT06691828 ↗ | Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948 Healthy Volunteer | PHASE1 | Completed | 2024-11-28 |
| NCT06593457 ↗ | A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects Healthy Volunteers | PHASE1 | Completed | 2024-10-29 |
| NCT05107739 ↗ | A Study of DeTIL-0255 in Adults With Advanced Malignancies Platinum-resistant Ovarian Cancer, Endometrial Cancer | PHASE1 | Terminated | 2023-05-09 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-11 | Reg FDOtherExhibits | filing ↗ |
| 2026-06-08 | Material agreementReg FDExhibits | filing ↗ |
| 2026-05-15 | Shareholder voteExhibits | filing ↗ |
| 2026-04-08 | ResultsExhibits | filing ↗ |
| 2026-03-06 | OtherExhibits | filing ↗ |
| 2026-01-28 | ResultsExhibits | filing ↗ |
| 2026-01-12 | Reg FDExhibits | filing ↗ |
| 2025-12-09 | Reg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-11 | 2026-06-11 | 0001549595-26-000034 ↗ |
| 8-K | 2026-06-08 | 2026-06-06 | 0001549595-26-000030 ↗ |
| 8-K | 2026-05-15 | 2026-05-15 | 0001549595-26-000028 ↗ |
| 10-Q | 2026-04-08 | 2026-02-28 | 0001549595-26-000025 ↗ |
| 8-K | 2026-04-08 | 2026-04-08 | 0001549595-26-000024 ↗ |
| 8-K | 2026-03-06 | 2026-03-06 | 0001193125-26-096734 ↗ |
| 10-K | 2026-01-28 | 2025-11-30 | 0001549595-26-000016 ↗ |
| 8-K | 2026-01-28 | 2026-01-28 | 0001549595-26-000013 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001549595-26-000003 ↗ |
| 8-K | 2025-12-09 | 2025-12-06 | 0001549595-25-000121 ↗ |
| 8-K | 2025-11-10 | 2025-11-06 | 0001549595-25-000117 ↗ |
| 8-K | 2025-10-22 | 2025-10-22 | 0001193125-25-246964 ↗ |